All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide
All
  • All
  • ELISA Kit
  • Protein
  • Antibody
  • Molecular Biology Product
  • Small Molecule
  • Peptide

TMEFF2 (US20190359711A1 Biosimilar) Recombinant Monoclonal Antibody

Datasheet
Code CSB-RA883439MB1HU
Size US$9799
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Q9UIK5
Target Names
TMEFF2
Alternative Names
Cancer/testis antigen family 120 member 2 antibody; CT120.2 antibody; HPP 1 antibody; HPP1 antibody; Hyperplastic polyposis protein 1 antibody; TEFF 2 antibody; TEFF2 antibody; TEFF2_HUMAN antibody; TENB 2 antibody; TENB2 antibody; TMEFF2 antibody; Tomoregulin antibody; Tomoregulin-2 antibody; TPEF antibody; TR 2 antibody; TR antibody; TR-2 antibody; Transmembrane protein containing epidermal growth factor and follistatin domains antibody; Transmembrane protein TENB2 antibody; Transmembrane protein with EGF like and two follistatin like domains 2 antibody; Transmembrane protein with EGF-like and two follistatin-like domains antibody
Species Reactivity
Human
Immunogen
Recombinant Human TMEFF2 protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
0.01M PBS，pH7.4
Form
Liquid
Troubleshooting and FAQs
Antibody FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Notes
Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity > 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
Lead Time
In stock
Description

This recombinant monoclonal antibody targets TMEFF2 (transmembrane protein with EGF-like and two follistatin-like domains 2), a type I transmembrane protein that functions as a modulator of cellular signaling pathways. TMEFF2 contains epidermal growth factor-like and follistatin-like domains, suggesting roles in growth factor signaling and protein-protein interactions. This protein is predominantly expressed in the brain and prostate tissue, where it influences cell survival, differentiation, and oncogenic processes. TMEFF2 has emerged as a significant biomarker in prostate cancer research, as it exhibits elevated expression in prostate tumors and correlates with disease progression, making it a promising therapeutic target for oncology research.

This antibody is designed based on the reference antibody described in patent US20190359711A1, which characterizes monoclonal antibodies with specific binding affinity to TMEFF2. The biosimilar provides researchers with a valuable tool for investigating TMEFF2's role in cancer biology, signal transduction mechanisms, and potential therapeutic interventions. It is particularly suited for studies exploring prostate cancer pathogenesis, tumor progression, and the development of targeted immunotherapeutic approaches.

Usage
It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

Related Products

TMEFF2 Antibodies

TMEFF2 Proteins

Customer Reviews and Q&A

■ Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
May be a survival factor for hippocampal and mesencephalic neurons. The shedded form up-regulates cancer cell proliferation, probably by promoting ERK1/2 phosphorylation.
Gene References into Functions
  1. Differential TMEFF2 processing from a single transmembrane protein may be a general mechanism to modulate transmembrane protein levels and domains, dependent on the repertoire of ADAMs or TTSPs expressed by the target cell. PMID: 28762604
  2. TMEFF2 methylation is associated with clear cell renal cell carcinoma. PMID: 28128743
  3. Results suggest that TMEFF2 is a brain-enriched endogenous modulator of Abeta neurotoxicity and an enhancer of alpha-secretase processing of AbetaPP PMID: 26402097
  4. TMEFF2 regulates the non-canonical activin/BMP4 signaling, PI3K, and Ras/ERK1/2 pathways. PMID: 25573902
  5. c-Myc contributes to the epigenetic regulation of HPP1 via the dominant recruitment of HDAC3. PMID: 24919179
  6. TMEFF2 acts as a tumor suppressor in gastric cancer through direct interaction with SHP-1 and can be a potential biomarker of carcinogenesis. PMID: 24987055
  7. TMEFF2 and SARDH cooperate to modulate one-carbon metabolism and invasion of prostate cancer cells. PMID: 23824605
  8. Androgen signaling promotes eIF2alpha phosphorylation and subsequent translation of TMEFF2 via a mechanism that requires uORFs in the 5'-UTR of TMEFF2. PMID: 23405127
  9. Methylation of TMEFF2 gene is associated with colorectal neoplasia in ulcerative colitis and Crohn's colitis. PMID: 22532293
  10. Findings suggest that methylation-associated down-regulation of TMEFF2 gene may be involved in lung tumorigenesis and TMEFF2 methylation can serve as a specific blood-based biomarker for NSCLC. PMID: 22814847
  11. Several genes expressed at exceptionally high levels were identified associated with early oocyte development, TMEFF2, the Rho-GTPase-activating protein oligophrenin 1 (OPHN1) and the mitochondrial-encoded ATPase6 (ATP6). PMID: 22238370
  12. TMEFF2 can function to regulate PDGF signaling; it is hypermethylated and downregulated in glioma and several other cancers PMID: 21559523
  13. the tumor suppressor activity of TMEFF2 requires the cytoplasmic/transmembrane portion of the protein and correlates with its ability to bind to SARDH and to modulate the level of sarcosine. PMID: 21393249
  14. GDF15, HSPA2, TMEFF2, and VIM were identified as epigenetic biomarkers for Bladder cancer. PMID: 20975101
  15. Hypermethylation of HPP1 is associated with hMLH1 hypermethylation in gastric adenocarcinomas. PMID: 12384516
  16. Aberrant methylation of the HPP1 gene is a relative common early event in ulcerative colitis-associated colorectal carcinoma. PMID: 12460892
  17. inverse correlation between TMEFF2 and c-Myc expression PMID: 12729735
  18. Hypermethylation of p16, RUNX3, and HPP1 in Barreett exophagus may represent independent risk factors for the progression of Barrett esophagus to esophageal cancer. PMID: 15824739
  19. A secreted form of TMEFF2 is expressed from TMEFF2 locus and may functionally interact with full-length TMEFF2, or its binding partners, and may also influence current immune-based treatment strategies PMID: 16439095
  20. Hypermethylation of HPP1 is associated with primary adenocarcinomas of the small bowel PMID: 16619216
  21. Methylation testing of fecal DNA using a panel of epigenetic markers (methylated SFRP2, HPP1 and MGMT) may be a simple and promising non-invasive screening method for colorectal carcinoma and precancerous lesions. PMID: 17352030
  22. TMEFF2 contributes to cell proliferation in an ADAM17-dependent autocrine fashion in cells expressing this protein PMID: 17942404
  23. data provides evidence to support the role of HPP1 as a tumor suppressor gene; activation of the STAT1 pathway likely represents the principal mediator of HPP1's tumor suppressive properties PMID: 18059030
  24. Methylated PAX6- or TPEF-promoters could represent biomarkers for bladder cancer. PMID: 18070176
  25. Distinct TPEF/HPP1 (transmembrane protein containing epidermal growth factor) gene methylation patterns in gastric cancer indicate a field effect in gastric carcinogenesis. PMID: 18799374
  26. promoter of TPEF gene is frequently hpermethylated, and associated with loss of TPEF mRNA expression in esophageal squamous cell carcinoma PMID: 19040536
  27. Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. PMID: 19288010
  28. Analysis of DNA from peripheral blood revealed that TPEF methylation was detectable in colorectal tumor patients and patients with early or pre-neoplastic lesions, but not in healthy volunteers. PMID: 15068392

Show More

Hide All

Subcellular Location
[Isoform 1]: Membrane; Single-pass type I membrane protein.; [Isoform 2]: Membrane; Single-pass type I membrane protein.; [Isoform 3]: Secreted.
Protein Families
Tomoregulin family
Tissue Specificity
Highly expressed in adult and fetal brain, spinal cord and prostate. Expressed in all brain regions except the pituitary gland, with highest levels in amygdala and corpus callosum. Expressed in the pericryptal myofibroblasts and other stromal cells of nor
Database Links

HGNC: 11867

OMIM: 605734

KEGG: hsa:23671

STRING: 9606.ENSP00000272771

UniGene: Hs.144513

Promotions
Reward For Reviews
Free antibody trial
Contact Us

  Email: [email protected]
  Distributors Worldwide

Service

Phage Display Service

Antibody Service

Protein Service

Gene Synthesis Service

Oligo Synthesis Service

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of email
Email
[email protected]
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2026 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Privacy Policy
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*